[
  {
    "ts": "2025-12-05T01:15:00+00:00",
    "headline": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "be3f7559-4bc4-3429-b76f-84bffe5fcc85",
      "content": {
        "id": "be3f7559-4bc4-3429-b76f-84bffe5fcc85",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
        "description": "",
        "summary": "PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
        "pubDate": "2025-12-05T01:15:00Z",
        "displayTime": "2025-12-05T01:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884",
          "originalWidth": 480,
          "originalHeight": 320,
          "caption": "Product image for download (Photo: Bristol Myers Squibb)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8OaCGv9qJtwcUw0gllRSKg--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884.cf.webp",
              "width": 480,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.vXnBRdM8psBefdqqhnW9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-breyanzi-approved-011500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T10:00:00+00:00",
    "headline": "Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use",
    "summary": "Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.",
    "url": "https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "cc09af30-0e94-32a6-a7de-b87472c6e5ea",
      "content": {
        "id": "cc09af30-0e94-32a6-a7de-b87472c6e5ea",
        "contentType": "STORY",
        "title": "Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use",
        "description": "",
        "summary": "Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.",
        "pubDate": "2025-12-05T10:00:00Z",
        "displayTime": "2025-12-05T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/praxis-soars-higher-bristol-myers-100000382.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PRAX"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "DNLI"
            },
            {
              "symbol": "CBIO"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T14:42:00+00:00",
    "headline": "Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?",
    "summary": "Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.",
    "url": "https://finance.yahoo.com/news/breyanzis-label-expansion-boost-bmys-144200340.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "90f9e684-aa54-33f1-8172-0761a1f6514e",
      "content": {
        "id": "90f9e684-aa54-33f1-8172-0761a1f6514e",
        "contentType": "STORY",
        "title": "Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?",
        "description": "",
        "summary": "Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.",
        "pubDate": "2025-12-05T14:42:00Z",
        "displayTime": "2025-12-05T14:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/breyanzis-label-expansion-boost-bmys-144200340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/breyanzis-label-expansion-boost-bmys-144200340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]